HC Wainwright Reiterates Buy Rating for OptiNose (NASDAQ:OPTN)

HC Wainwright restated their buy rating on shares of OptiNose (NASDAQ:OPTN - Free Report) in a research report report published on Monday morning, Benzinga reports. The firm currently has a $5.00 target price on the stock.

Separately, Lake Street Capital increased their target price on shares of OptiNose from $3.00 to $4.00 and gave the stock a buy rating in a research note on Monday, March 18th.

OptiNose Stock Performance

NASDAQ:OPTN remained flat at $0.86 during trading hours on Monday. The company's stock had a trading volume of 1,373,889 shares, compared to its average volume of 868,342. OptiNose has a one year low of $0.80 and a one year high of $2.10. The stock has a fifty day moving average price of $1.46 and a 200 day moving average price of $1.32. The company has a market capitalization of $96.79 million, a price-to-earnings ratio of -2.69 and a beta of -0.24.

OptiNose (NASDAQ:OPTN - Get Free Report) last posted its earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. The firm had revenue of $19.87 million for the quarter, compared to analysts' expectations of $19.90 million. During the same period last year, the firm earned ($0.17) earnings per share. On average, equities analysts anticipate that OptiNose will post -0.26 earnings per share for the current year.

Insider Buying and Selling

In other OptiNose news, insider Michael F. Marino III sold 15,059 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $1.88, for a total transaction of $28,310.92. Following the transaction, the insider now directly owns 602,268 shares of the company's stock, valued at $1,132,263.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other OptiNose news, insider Michael F. Marino III sold 15,059 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $1.88, for a total transaction of $28,310.92. Following the completion of the transaction, the insider now owns 602,268 shares of the company's stock, valued at $1,132,263.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ramy A. Mahmoud sold 52,875 shares of OptiNose stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $1.31, for a total value of $69,266.25. Following the completion of the sale, the chief executive officer now directly owns 548,387 shares in the company, valued at $718,386.97. The disclosure for this sale can be found here. In the last quarter, insiders sold 89,477 shares of company stock valued at $138,078. 2.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OptiNose

Large investors have recently modified their holdings of the business. HighMark Wealth Management LLC acquired a new position in shares of OptiNose during the 1st quarter worth approximately $36,000. Assenagon Asset Management S.A. grew its holdings in OptiNose by 139.1% in the 1st quarter. Assenagon Asset Management S.A. now owns 87,096 shares of the company's stock valued at $127,000 after buying an additional 50,662 shares in the last quarter. Kingdon Capital Management L.L.C. increased its stake in shares of OptiNose by 5.4% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,899,237 shares of the company's stock worth $5,030,000 after acquiring an additional 200,000 shares during the last quarter. MVM Partners LLC acquired a new position in shares of OptiNose during the 4th quarter valued at about $18,768,000. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of OptiNose in the fourth quarter valued at about $33,000. Hedge funds and other institutional investors own 85.60% of the company's stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.